UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

Bridgette J. Picou, LVN, ACLPN, presented research on the lived experiences of women living with HIV and going through ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

HIV conference opened in San Francisco Sunday, March 9, under a cloud of uncertainty in the face of the Trump ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UCSF has found.

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...

The following is a summary of ““Let me hear what you’re needing”: exploring how HIV providers conceptualize patient-provider ...

Children exposed to HIV and antiretroviral (ARV) treatments during pregnancy face a higher risk of developing ...